Anavex Life Sciences has revealed promising findings from a recent phase 2b/3 trial exploring the
efficacy of blarcamesine (ANAVEX2-73) in treating early Alzheimer’s disease.
This investigational therapy demonstrated significant reductions in
pathological amyloid-β levels and slowed brain atrophy, providing hope for
millions affected by this debilitating condition.
The trial enrolled 508 participants with early symptomatic Alzheimer’s disease, who were
randomized to receive either blarcamesine or a placebo for 48 weeks. Conducted
across 52 medical research centers in five countries, the study aimed to assess
the cognitive and functional efficacy of blarcamesine using the Alzheimer’s
Disease Assessment Scale-Cognitive (ADAS-Cog) and the Alzheimer’s Disease
Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales as primary endpoints.
Results showed a notable reduction in amyloid-β biomarkers with blarcamesine treatment,
substantiating the therapy’s strong anti-amyloid effect. Additionally, MRI
scans indicated a significant reduction in brain volume loss among those
treated with blarcamesine. According to Anavex Life Sciences, these findings mark an important milestone in
Alzheimer’s research.
“These outcomes are very encouraging, particularly in a study that can demonstrate
objective slowing of neurodegeneration markers,” said Michael Weiner, MD,
professor of radiology and biomedical imaging at the University of California,
San Francisco.
The safety profile of blarcamesine also proved favorable, with transient dizziness being the most
common adverse event reported. This side effect was generally mild to moderate in severity.
Christopher U Missling, PhD, president and CEO of Anavex Life Sciences, expressed gratitude
to all study participants and emphasized the company’s commitment to advancing
blarcamesine as a potential new treatment option for Alzheimer’s disease.
As Anavex continues to innovate in Alzheimer’s research, the medical community
remains optimistic about the future prospects of blarcamesine and its potential
to alter the course of this devastating disease.
Refer to this article, for related information.
Follow their page on https://twitter.com/AnavexLifeSci